Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 9/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 9/20 | 0.55 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926667 | 1.00 | MMP9 (0.57) | MMP9TDP1MMP2ADAMTS4CA2 | |
| SCHEMBL8018411 | 0.88 | MMP9 (0.61) | MMP9TDP1MMP2ADAMTS4CA2 | |
| SCHEMBL617758 | 0.87 | MMP9 (0.60) | MMP9TDP1MMP2ADAMTS4CA2 | |
| SCHEMBL5481551 | 0.87 | MMP9 (0.60) | MMP9TDP1MMP2ADAMTS4CA2 | |
| SCHEMBL433896 | 0.85 | MMP9 (0.67) | MMP9TDP1MMP2ADAMTS4CA2 | |
| SCHEMBL561566 | 0.85 | MMP9 (0.67) | MMP9TDP1MMP2ADAMTS4CA2 | |
| SCHEMBL29961332 | 0.84 | MMP9 (0.63) | MMP9TDP1MMP2ADAMTS4CA2 | |
| SCHEMBL15213296 | 0.84 | MMP9 (0.63) | MMP9TDP1MMP2ADAMTS4CA2 | |
| SCHEMBL14519991 | 0.84 | MMP9 (0.63) | MMP9TDP1MMP2ADAMTS4CA2 | |
| SCHEMBL6331296 | 0.83 | MMP9 (0.61) | MMP9TDP1MMP2ADAMTS4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103221069-A | Alumina nanoparticle bioconjugates and methods of stimulating an immune response using said bioconjugates | PROVIDENCE HEALTH & SERVICES OREGON | 2013-07-24 | — | — | CN | disclosed |
| EP-1066315-B1 | USE OF INHIBITORS OF MAMMALIAN ASPARAGINYL ENDOPEPTIDASE FOR MODULATING THE IMMUNE SYSTEM | UNIV DUNDEE (GB) | 2008-05-28 | — | — | EP | disclosed |
| US-20070269832-A1 | Novel affinity labels | IMMUNOCHEMISTRY TECHNOLOGIES, LLC | 2007-11-22 | — | — | US | disclosed |
| US-20060286091-A1 | RelA-ASSOCIATED INHIBITOR, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF | CITY OF NAGOYA (JP) | 2006-12-21 | — | — | US | disclosed |
| US-7119169-B2 | RelA-associated inhibitor, process for producing the same and utilization thereof | CITY OF NAGOYA (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20060148023-A1 | Affinity labeling of serine proteases for simultaneous detection of multiple serine protease activity levels | IMMUNOCHEMISTRY TECHNOLOGIES, LLC | 2006-07-06 | — | — | US | disclosed |
| US-20050136492-A1 | Affinity labeling of enzymes for detection of enzyme activity level in living cells | IMMUNOCHEMISTRY TECHNOLOGIES, LLC | 2005-06-23 | — | — | US | disclosed |
| US-20030148396-A1 | RelA-associated inhibitor, process for producing the same and utilization thereof | ONO PHARMACEUTICAL CO., LTD. | 2003-08-07 | — | — | US | disclosed |
| WO-2003060466-A2 | AFFINITY LABELING OF SERINE PROTEASES FOR SIMULTANEOUS DETECTION OF MULTIPLE SERINE PROTEASE ACTIVITY LEVELS | IMMUNOCHEMISTRY TECHNOLOGIES, LLC (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059877-A2 | NOVEL AFFINITY LABELS | IMMUNOCHEMISTRY TECHNOLOGIES, LLC (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-1066315-A1 | USE OF INHIBITORS OF MAMMALIAN ASPARAGINYL ENDOPEPTIDASE FOR THERAPY OF AUTOIMMUNE DISEASE | UNIVERSITY OF DUNDEE (GB) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048910-A1 | USE OF INHIBITORS OF MAMMALIAN ASPARAGINYL ENDOPEPTIDASE FOR THERAPY OF AUTOIMMUNE DISEASE | UNIVERSITY OF DUNDEE (GB) | 1999-09-30 | — | — | WO | disclosed |
| US-5762939-A | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus | MG-PMC, LLC (US) | 1998-06-09 | — | — | US | disclosed |
| US-5708148-A | MUTANTS OF ESCHERICHIA COLI CELLS, DENATURING POLYPEPTIDES, REFOLDING AND INCUBATION | CIBA GEIGY CORPORATION (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0434605-B1 | Novel process for the production of unfused protein in E. coli | CIBA GEIGY AG (CH) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995035366-A1 | ANIMAL MODEL FOR ALZHEIMER'S DISEASE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-12-28 | — | — | WO | disclosed |
| EP-0541058-A1 | Expression of a mature proteinase 2a, its partial purification and preparation of inhibitory active substrates | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 1993-05-12 | — | — | EP | disclosed |
| WO-1993000926-A1 | TREATMENT OF PERIODONTAL DISEASE WITH PROTEASE INHIBITORS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1993-01-21 | — | — | WO | disclosed |
| EP-0434605-A2 | Novel process for the production of unfused protein in E. coli | CIBA-GEIGY AG (CH) | 1991-06-26 | — | — | EP | disclosed |
| US-4906571-A | Cell surface modification using a novel glycoproteinase of pasteurella haemolytica | UNIVERSITY OF GUELPH (CA) | 1990-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070269832-A1 | Novel affinity labels | ANPEP, SLC7A1, DNPEP | MMP9 421/4885TDP1 3174/4885MMP2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.